Clinical Trial Search

Primary: Number of Participants Achieving a Composite Endpoint of Initiation of Maintenance Dialysis or All-cause Mortality — 35; 46 Participants — p=.1602

Primary: Number of Participants With Treatment-related Adverse Events — 0 Participants

Primary: Achievement of a ≥ 30% Reduction in Mean PTH From Baseline to During the Efficacy Assessment Phase at Month 6 (Weeks 22 to 26) — 96; 58; 57; 93 participants — p=<0.0001

Primary: Change in Daily Urine Volume From Baseline — 18.3 mL

Primary: QOL: Kidney Disease Quality of Life (KDQOL36) — 74; 72 score on a scale

Primary: Change From Baseline in Daily Urine Volume — 481.0 ml

Primary: Hemoglobin Concentration at 6 Months — 117; 113 g/L

Primary: Phosphorus Levels — 5.3; 5.6; 5.4; 6 mg/dL

Primary: Percentage of Subjects With Hypercalcemia — 15.3 percentage of participants

Primary: Efficacy of Mannitol Administration in Reducing the Frequency of Intra-dialytic Hypotension (Decline in Systolic Blood Pressure) During the First Three Hemodialysis…

Primary: Reduction Ratio of Lambda Immunoglobulin FLC at Week 24 — 32.156; 17.514 percentage ratio

Primary: Patients With an Increase in Hemoglobin >= 1gm/dL. — 35; 23 participants

Primary: Ertapenem Transmembrane Clearance by Continuous Hemodialysis. — 10.4 mL/min

Primary: Change From Baseline (BL) to the Average Hemoglobin (Hb) in Weeks 28-36 Without Rescue Therapy [EU (EMA)] — 0.428; 0.193 g/dL — p=<0.001

Primary: The Change in Serum Phosphorus for MCI-196 and Sevelamer — -1.23; -1.47; -2.26 mg / dL

Primary: Mean Change in Hemoglobin Between Baseline and the Evaluation Period — 11.20; 11.21; 11.13; 11.05 g/dL

Primary: Mean Change in Hemoglobin Between Baseline and the Evaluation Period — 11.30; 11.32; 11.06; 11.25 g/dL

Primary: Change From Pre-dose Average in Hemoglobin (Hgb) Level to The Mid-study Average — 10.43; 10.55; 10.52; 0.00 Grams per deciliter (g/dL)

Primary: Change From Baseline in Serum Phosphorus Concentrations at the End of Treatment. — -1.84; -2.59; -3.17; -3.78 mg/dL

Primary: Time to Composite of All-Cause Mortality and Non-Fatal Cardiovascular Events (Myocardial Infarction, Stroke) Defined as Time Between First Dose of Study Medication and…

Primary: Percentage of Participants Maintaining Mean Hemoglobin Levels Within the Target Range During the Last 4 Weeks of the Treatment Period (Weeks 8 to 12) — 57.89 Percentage…

Primary: Percentage of Participants Who Maintained Average Hb Value Within Target Range During the EEP — 50.0 percentage of participants

Primary: The Achievement of Two Consecutive Greater Than or Equal to 30% Decreases From Baseline Intact Parathyroid Hormone Levels — 93; 57; 12; 45 participants

Primary: Percent of Subjects Whose Hemoglobin (Hgb) Decreases by a Total of 1.0 Grams/ Deciliter (g/dL) (or More) From Baseline on Each of Two Successive Measurements. — 5; 6; 5…

Primary: Change in Baseline and 2 Week FMD/VP Measurements Between Sildenafil Group and Placebo Group — 10.8; 8.6 Change in FMD%

Primary: Percentage of Subjects With ≥ 50% Decrease From Baseline in Intact Parathyroid Hormone (iPTH) Serum Level — 53.3; 41.9; 38.7; 56.7 Percentage of participants

Primary: Percentage of Participants Maintaining Mean Hemoglobin Concentration Within +/- 1 g/dL of Their Reference Hb and Between 10.5 and 12.5 g/dL During Efficacy Evaluation…

Primary: Number of Participants With Hemoglobin Values Within the Target Range of 11-12 g/dL at Visit 2 (Month 1) — 23 participants

Primary: Change From Baseline in Daily Urine Volume — 169.2; 111.8; -259.9 mL

Primary: Change From Baseline to 12 Weeks in Systolic Ambulatory Blood Pressure in the Chlorthalidone Group Compared to Placebo. — -11.0; -0.5 mm Hg